Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoven versus Vaminolact in premature very low birth weight infants requiring parenteral nutrition
2009-012602-39Phase 3Terminated
- Sponsor
- Fresenius Kabi
- Start
- Feb 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing Neoven with Vaminolact (2 arms). Primary endpoints: Hyperammonemia, Azotemia and 3 more. Started Feb 2010; status: terminated.
02
Drugs
NeovenVaminolact
Beyond the preview
Go deeper on 2009-012602-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012602-39.